Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.

Oncologist · 2010 · PMC3227898 · PMID 20930098

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

did not reach statistical significancep = .085so close (0.05 < p ≤ 0.1)

After a median follow-up time of 52 months, patients receiving L-BLP25 had a median overall survival time of 17.2 months compared with 13.0 months in the control arm, although this difference did not reach statistical significance (HR 0.75, adjusted p = .085).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.